UI Hospitals and Clinics
Participants in this research have ductal carcinoma in situ (DCIS), an early change in the breast that could become breast cancer in the future. DCIS cells are sensitive to hormones, and therefore may be treatable with anti-hormonal medications. Standard treatment for DCIS includes surgery to remove the DCIS cells from the breast, or surgery followed by radiation therapy. The purpose of this study is to test whether neoadjuvant (neoadjuvant means given before surgery) treatment with the aromatase inhibitor (anti-hormonal medication) letrozole has an effect, either good or bad, on the participants and on the DCIS. Mammograms are the standard method of detecting and measuring DCIS. The researchers conducting this study would also like to learn more about whether Magnetic Resonance Imaging (MRI) may be better for evaluating and measuring DCIS, compared to mammograms. (An MRI scan is a radiology technique that produces images of the body using magnets, not X-rays.) Approximately six people will take part in this study conducted by investigators at the University of Iowa. Approximately 106 women will take part in this study nationwide.
Clarine Halvorsen, 319-356-3944
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.